These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18370450)

  • 1. Lanreotide Autogel: a review of its use in the management of acromegaly.
    Croxtall JD; Scott LJ
    Drugs; 2008; 68(5):711-23. PubMed ID: 18370450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on lanreotide Autogel in acromegaly.
    Croxtall JD; Scott LJ
    BioDrugs; 2008; 22(4):275-7. PubMed ID: 18611070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lanreotide autogel(®): a review of its use in the treatment of patients with acromegaly.
    Burness CB; Dhillon S; Keam SJ
    Drugs; 2014 Sep; 74(14):1673-91. PubMed ID: 25193626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly.
    Murray RD; Melmed S
    J Clin Endocrinol Metab; 2008 Aug; 93(8):2957-68. PubMed ID: 18477663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium.
    Ciccarelli A; Daly A; Beckers A
    Treat Endocrinol; 2004; 3(2):77-81. PubMed ID: 15743103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic evaluation of lanreotide.
    Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1301-12. PubMed ID: 20716034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lanreotide autogel in acromegaly - a decade on.
    Kyriakakis N; Chau V; Lynch J; Orme SM; Murray RD
    Expert Opin Pharmacother; 2014 Dec; 15(18):2681-92. PubMed ID: 25307803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center open-label study to investigate the efficacy and safety of repeated subcutaneous injections of lanreotide Autogel in patients with acromegaly previously treated with octreotide.
    Kelly P; Maher KT; Chew SL; Monson JP; Grossman AB; Jenkins PJ
    Endocr Pract; 2010; 16(2):191-7. PubMed ID: 19833584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.
    Lucas T; Astorga R;
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):320-6. PubMed ID: 16918950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).
    Gutt B; Bidlingmaier M; Kretschmar K; Dieterle C; Steffin B; Schopohl J
    Exp Clin Endocrinol Diabetes; 2005 Mar; 113(3):139-44. PubMed ID: 15789272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
    Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
    Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly.
    Caron P; Beckers A; Cullen DR; Goth MI; Gutt B; Laurberg P; Pico AM; Valimaki M; Zgliczynski W
    J Clin Endocrinol Metab; 2002 Jan; 87(1):99-104. PubMed ID: 11788630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly.
    Salvatori R; Nachtigall LB; Cook DM; Bonert V; Molitch ME; Blethen S; Chang S;
    Pituitary; 2010 Jun; 13(2):115-22. PubMed ID: 19898989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
    Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
    Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Somatuline(R) Autogel(R), a new formulation of lanreotide for the treatment of acromegalic patients].
    Caron P
    Ann Endocrinol (Paris); 2002 Apr; 63(2 Pt 3):2S19-24. PubMed ID: 12037499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.